Lauro et al., 2021 - Google Patents
Could antigen presenting cells represent a protective element during sars-cov-2 infection in children?Lauro et al., 2021
View HTML- Document ID
- 7387202838965285508
- Author
- Lauro R
- Irrera N
- Eid A
- Bitto A
- Publication year
- Publication venue
- Pathogens
External Links
Snippet
Antigen Presenting Cells (APC) are immune cells that recognize, process, and present antigens to lymphocytes. APCs are among the earliest immune responders against an antigen. Thus, in patients with COVID-19, a disease caused by the newly reported SARS …
- 241001678559 COVID-19 virus 0 title abstract description 112
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Callahan et al. | The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner | |
| Ashley et al. | Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression | |
| Blaess et al. | COVID-19/SARS-CoV-2 infection: lysosomes and lysosomotropism implicate new treatment strategies and personal risks | |
| Ezeonwumelu et al. | JAK-STAT pathway: A novel target to tackle viral infections | |
| Ricci et al. | Innate immune response to SARS-CoV-2 infection: From cells to soluble mediators | |
| Ingle et al. | Distinct effects of type I and III interferons on enteric viruses | |
| Kozlov et al. | Involvement of oxidative stress and the innate immune system in SARS-CoV-2 infection | |
| Bosch-Barrera et al. | Silibinin and SARS-CoV-2: dual targeting of host cytokine storm and virus replication machinery for clinical management of COVID-19 patients | |
| Kayesh et al. | An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants | |
| Palermo et al. | Type I interferons in COVID-19 pathogenesis | |
| Cong et al. | The interaction between nidovirales and autophagy components | |
| Kaivola et al. | Inflammasomes and SARS-CoV-2 infection | |
| McGill et al. | SARS–CoV-2 immuno-pathogenesis and potential for diverse vaccines and therapies: opportunities and challenges | |
| Seong et al. | Zika virus-induction of the suppressor of cytokine signaling 1/3 contributes to the modulation of viral replication | |
| Eisfeld et al. | Viral glycoproteins induce NLRP3 inflammasome activation and pyroptosis in macrophages | |
| Lauro et al. | Could antigen presenting cells represent a protective element during sars-cov-2 infection in children? | |
| Jung et al. | Contribution of dendritic cells in protective immunity against respiratory syncytial virus infection | |
| Kim et al. | Human coronavirus OC43 as a low-risk model to study COVID-19 | |
| Siri et al. | Autophagy, unfolded protein response, and neuropilin-1 cross-talk in SARS-CoV-2 infection: What can be learned from other coronaviruses | |
| Anthony et al. | Filoviruses: one of these things is (not) like the other | |
| Farrag et al. | SARS-CoV-2: an overview of virus genetics, transmission, and immunopathogenesis | |
| Stephens et al. | Function and modulation of type I interferons during respiratory syncytial virus infection | |
| Zhang et al. | An overview of current knowledge of deadly CoVs and their interface with innate immunity | |
| Alturaiki | Considerations for novel COVID-19 mucosal vaccine development | |
| Chen et al. | Novel antiviral strategies in the treatment of COVID-19: a review |